
LRG, Human, mAb 2F5.A2
The monoclonal antibody recognizes leucine-rich alpha-2-glycoprotein (LRG), a member of the leucine-rich repeat family. LRG is a plasma protein of approximately 50 kDa. LRG consists of 312 amino acids. It has 1 galactosamine and 4 glucosamine oliogosacharides attached and has 2 intrachain disulfide bonds. Leucine comprises 66 of the 312 amino acids, and LRG contains at least eight 24-amino acid leucine-rich repeats. The consensus of these residues, termed leucine-rich repeats (LRR), has been identified as an LRR-containing domain. The primary function of LRRs is to provide versatile structural framework of the formation of protein-protein interactions. LRG is expressed during granulocyte differentiation. Although several family members of the leucine-rich repeat family have been shown to be involved in signal transduction, protein-protein interaction, or cell adhesion and development, a function for LRG remains elusive. LRG has been reported as a biomarker for certain diseases including microbial infections and cancer. LRG can be detected in human neutrophils and progenitor cells, but not in peripheral blood mononuclear cells. The monoclonal antibody 2F5.A2 can be used for immuno purification of human LRG.
Calculate your ELISA data easily
With the ELISA calculator you can easily calculate ELISA data. Assayfit Pro helps to perform curve fitting. The calculator generates advanced reports, fit graph, fit parameters and goodness of fit are shown.
Latest Hycult Biotech news
- New Human Complement Pathway AssaysWe are very proud of our newly developed human classical and alternative complement pathway assays. They are produced in response to a growing demand for quantitative investigation of complement inhibitors or regulators at lower sample dilutions. This development aims to address the issue of false negative results, enabling more accurate and reliable analysis of complement… Read more: New Human Complement Pathway Assays
- Navigating the pitfalls in complement analysisOur colleague Erik Toonen shared his experience on how to analyze complement at the Complement-based Drug Development Summit in Boston in September 11-13th, 2023. He showed valuable insights on analyzing complements. For accurate complement analysis, it is important that not only the correct technique is used but also that pre-analytical sample handling is performed in… Read more: Navigating the pitfalls in complement analysis
- NEW Human C3d ELISAWe are happy to introduce our new ELISA (cat.# HK3017) designed to detect human C3d. What sets this assay apart is its utilization of a distinctive neo-epitope capture antibody that selectively targets a specific C3d region of the alpha chain, which is not available in other C3 variants. This way it specifically distinguishes C3d from native C3… Read more: NEW Human C3d ELISA